Premium
Evaluation of new chlorhexidine‐ and cetylpyridinium chloride‐based mouthrinse formulations adjunctive to scaling and root planing: pilot study
Author(s) -
GarcíaGargallo M,
Zurlohe M,
Montero E,
Alonso B,
Serrano J,
Sanz M,
Herrera D
Publication year - 2017
Publication title -
international journal of dental hygiene
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.674
H-Index - 38
eISSN - 1601-5037
pISSN - 1601-5029
DOI - 10.1111/idh.12254
Subject(s) - medicine , cetylpyridinium chloride , mcnemar's test , chlorhexidine , dentistry , scaling and root planing , chronic periodontitis , adverse effect , periodontitis , mathematics , pulmonary surfactant , statistics , physics , thermodynamics
Objective To compare the effect of two newly formulated chlorhexidine ( CHX ) and cetylpyridinium chloride ( CPC ) mouthrinses after scaling and root planing ( SRP ) in terms of clinical, microbiological, patient‐based variables and adverse events, with a positive control with the same active components, already marketed and tested. Methods A pilot, randomized clinical trial, double‐blind, parallel design with 1‐month follow‐up was conducted. Chronic periodontitis patients requiring non‐surgical periodontal therapy were enrolled and randomly assigned to: (i) SRP and test‐1 (new reformulation: 0.12% CHX and 0.05% CPC ); (ii) SRP and test‐2 (new formulation: 0.03% CHX and 0.05% CPC ); or (iii) SRP and positive control (commercial product: 0.12% CHX and 0.05% CPC ). All variables were evaluated at baseline and 1 month after SRP . Quantitative variables were compared by means of anova or Kruskal–Wallis test and qualitative variables by chi‐square or McNemar tests. Results Thirty patients (10 per group) were included. After 1 month, there were significant differences among groups in plaque levels ( P = 0.016) as test‐1 showed less sites with plaque than test‐2 (31.15% [standard error‐ SE 2.21%] versus 49.39% [ SE 4.60%), respectively). No significant differences were found for global patient perception of the product or in adverse effects. Test groups showed better results in levels and proportions ( P = 0.022) of Capnocytophaga spp. Conclusions Within the limitations of this pilot study, it can be concluded that the newly formulated 0.12% CHX and 0.05% CPC mouthrinse showed larger plaque level reductions, without showing more adverse effects, when compared to the other two mouthrinses, after SRP .